In this phase II , single-blinded , placebo-controlled study , 95 patients ( 57.2 9.6 years old , 85 % women , 83 % Caucasians ) with MNG ( median size 96.0 mL ; range 31.9-242 .2 mL ) were randomized to receive placebo ( n = 32 ) , 0.01 mg MRrhTSH ( n = 30 ) , or 0.03 mg MRrhTSH ( n = 33 ) 24 hours before a calculated ( 131 ) I activity .